MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.14
+0.39
+2.64%
After Hours: 15.37 +0.23 +1.49% 14:42 11/27 EST
OPEN
14.80
PREV CLOSE
14.75
HIGH
15.33
LOW
14.64
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
29.61
52 WEEK LOW
13.39
MARKET CAP
1.11B
P/E (TTM)
-5.2104
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 4d ago
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modifications
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing Phase 3 SIENDO study, the Data and Safety Monitoring Board (DSMB) has recommended that the study should continue, as previously planned, without the need for adding additional patients to the trial or amending the study protocol.
PR Newswire · 4d ago
Karyopharm's selinexor data from late-stage soft tissue cancer study in oral presentation
Karyopharm Therapeutics ([[KPTI]] -1.5%) has announced presentation of positive results from the Phase 3 portion of SEAL study evaluating single agent, oral XPOVIO (selinexor) versus matching placebo in patients with
Seekingalpha · 11/20 16:06
Karyopharm Therapeutics Reports Phase 3 SEAL Data In Oral Presentation At Connective Tissue Oncology Society 2020 Annual Meeting: 'Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Improvement in Median PFS...'
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present positive results from the Phase 3 portion of the randomized, double
Benzinga · 11/20 15:31
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 11/20 12:37
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15 15:14
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON (Bortezomib, Selinexor and Dexamethasone) study evaluating XPOVIO in patients with relapsed or refractory multiple myeloma were published online in The Lancet. The BOSTON study evaluated once weekly XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in combination with once weekly Velcade® (bortezomib) and low-dose dexamethasone against standard twice weekly Velcade in adult patients with multiple myeloma who had received one to three prior lines of therapy.
PR Newswire · 11/13 00:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KPTI. Analyze the recent business situations of Karyopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KPTI stock price target is 31.00 with a high estimate of 41.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 247
Institutional Holdings: 77.69M
% Owned: 105.56%
Shares Outstanding: 73.60M
TypeInstitutionsShares
Increased
54
8.86M
New
54
-8.10M
Decreased
53
5.37M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
President/Chief Scientific Officer
Sharon Shacham
Chief Executive Officer/Co-Founder/Director
Michael Kauffman
Chief Financial Officer/Senior Vice President/Treasurer
Michael Mason
Executive Vice President/General Counsel/Secretary
Christopher Primiano
Executive Vice President
Tanya Lewis
Executive Vice President
Jatin Shah
Senior Vice President/Director of Sales
Perry Monaco
Other
Ran Frenkel
Lead Director/Independent Director
Barry Greene
Director
Mansoor Mirza
Director
Christy Oliger
Independent Director
Garen Bohlin
Independent Director
Mikael Dolsten
Independent Director
Deepika Pakianathan
Independent Director
Deepa Pakianathan
Independent Director
Richard Paulson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KPTI
Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.